Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Aug 13, 2019 in Leukemia | 0 comments

In a nutshell

This study aimed to investigate if stem cell transplantation (SCT) could improve the long-term prognosis of minimal residual disease negative complete remission (MRD-CR) patients with acute lymphocytic leukemia (ALL) after chimeric antigen receptor-modified (CAR) T-cell therapy. 

This study concluded that this treatment regime was safe and effective for this group of patients.  

Some background

Chimeric antigen receptor-modified T-cell (CAR-T) therapy has been shown to be effective and safe for patients with relapsed or unresponsive B-cell acute lymphoblastic leukemia (ALL). CAR-T therapy is a treatment where a patient's T cells (immune cells) are changed in the lab so they will attack cancer cells. CAR-T therapy is limited in terms of long-term leukemia-free survival. New ways to help CAR-T therapy achieve a lasting effect are needed. 

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) involves taking cells from a healthy donor and transplanting them to a patient to make new cells. It was unknown if allo-HSCT could improve long-term outcomes for patients with ALL after they received CAR-T therapy. 

Methods & findings

This study involved patients with relapsed or unresponsive ALL. In the first stage, 58 patients received split doses of CART-T cells after lymphodepleting chemotherapy (kills leukemia blood cells before treatment). 87.9% of these patients achieved complete remission (CR – no signs of cancer left). In the second stage, 21 of 47 MRD-CR patients without previous allo-HSCT received allo-HSCT within 3 months after CAR-T therapy. The average follow-up was 7.7 months. 

There was no difference in overall survival (OS) between the MRD-CR patients who received allo-HSCT and those who did not. However, event-free survival (EFS; survival free of complications) and relapse-free survival (RFS; survival without the cancer coming back) were significantly prolonged by allo-HSCT in patients with a high number of cancer cells before the infusion and in those with poor prognostic markers.

The bottom line

This study concluded that CAR-T therapy before allo-HSCT is safe and effective for patients with relapsed or unresponsive ALL. It was also concluded that it may prolong EFS and RFS in cases of high pre-infusion remaining leukemia cells or poor prognostic markers. 

The fine print

This study had a very small sample size and a short duration of follow-up. Larger studies are needed.

Published By :

American Journal of Hematology

Date :

Jul 18, 2019

Original Title :

Anti-CD19 CAR-T Therapy Bridging to Allo-HSCT for Relapsed/refractory B-cell Acute Lymphoblastic Leukemia: An Open-Label Pragmatic Clinical Trial.

click here to get personalized updates